Increased Hepatic Expression of SARS-CoV-2 Entry Points and Proinflammatory Cytokines in Cirrhosis

Limón-de la Rosa, Nathaly; Cervantes-Álvarez, Eduardo; Navarro Álvarez, Nalu

doi:10.1016/j.cgh.2021.08.053

Increased Hepatic Expression of SARS-CoV-2 Entry Points and Proinflammatory Cytokines in Cirrhosis

Journal

Clinical Gastroenterology and Hepatology

ISSN

1542-3565

Date Issued

2022

Author(s)

Limón-de la Rosa, Nathaly

Cervantes-Álvarez, Eduardo

Navarro Álvarez, Nalu

Type

Resource Types::text::journal::journal article

DOI

10.1016/j.cgh.2021.08.053

URL

https://scripta.up.edu.mx/handle/20.500.12552/2172

Abstract

It has been recently reported that patients with cirrhosis have significantly higher mortality following severe acute respiratory syndrome coronavrisu 2 (SARS-CoV-2) infection compared with those without.1,2 Specifically, it was demonstrated that mortality was greater in those with advanced cirrhosis (Child-Pugh B and C), and that from cirrhotic patients experiencing SARS-CoV-2 infection, close to half suffer acute decompensation including acute-on-chronic liver failure (ACLF).2 Unfortunately, the presence of hepatic decompensation at baseline has been shown to be an independent predictor of all-cause mortality in patients with coronavirus disease 2019 (COVID-19).1 Patients with decompensated cirrhosis contracting COVID-19 have a poor outcome, with an overall reported mortality of over 30%.1.

Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.